Access Pharmaceuticals Signs Exclusive Specialty Distribution Agreement With BioScrip 

Agreement Provides Multi-level Distribution Of Lead Product, Including Inventory In Over 30 Top Metro Areas

 

DALLAS and NEW YORK, July 20 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) , a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has signed an exclusive specialty distribution agreement with BioScrip (NASDAQ:BIOS <http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=BIOS> ) for its lead product, MuGard -- an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. The agreement aligns the Company with comprehensive access to BioScrip's nationwide distribution platform and the ability to leverage the company's extensive physician relationships, 110 BioScrip specialty pharmacies, mail distribution capability and diversified payor network.